schliessen

Filtern

 

Bibliotheken

HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice

Suicide gene therapy using ganciclovir (GCV) with transfection of the herpes thymidine kinase (HSVtk) gene has been studied for cancer therapy. The present study demonstrates an efficient method of suicide gene therapy for multiple hepatic tumors, involving repetitive transfection of the HSVtk gene... Full description

Journal Title: Gene therapy January 2001, Vol.8(1), pp.80-3
Main Author: Hirano, T
Other Authors: Kaneko, S , Kaneda, Y , Saito, I , Tamaoki, T , Furuyama, J , Tamaoki, T , Kobayashi, K , Ueki, T , Fujimoto, J
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0969-7128 ; PMID: 11402306 Version:1
Link: http://pubmed.gov/11402306
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline11402306
title: HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
format: Article
creator:
  • Hirano, T
  • Kaneko, S
  • Kaneda, Y
  • Saito, I
  • Tamaoki, T
  • Furuyama, J
  • Tamaoki, T
  • Kobayashi, K
  • Ueki, T
  • Fujimoto, J
subjects:
  • Genetic Therapy -- Methods
  • Liver Neoplasms, Experimental -- Therapy
  • Promoter Regions, Genetic -- Genetics
  • Transfection -- Methods
  • Alpha-Fetoproteins -- Genetics
ispartof: Gene therapy, January 2001, Vol.8(1), pp.80-3
description: Suicide gene therapy using ganciclovir (GCV) with transfection of the herpes thymidine kinase (HSVtk) gene has been studied for cancer therapy. The present study demonstrates an efficient method of suicide gene therapy for multiple hepatic tumors, involving repetitive transfection of the HSVtk gene driven by the alpha-fetoprotein (AFP) promoter using hemagglutinating virus of Japan (HVJ)-liposomes. AFP-producing cells (HUH7) and AFP-nonproducing cells (LS180) were injected subcutaneously (s.c.) to establish tumors in nude mice. Two plasmid constructs, bacterial LacZ gene driven by the AFP promoter (AFPLacZ), and HSVtk gene driven by the AFP promoter (AFPTK1) were encapsulated into the HVJ-liposome and used. When AFPLacZ was injected into the s.c. tumors, expression of LacZ gene was confined to HUH7 tumors. Repeated transfection of AFPTK1 followed by GCV treatment markedly suppressed growth of HUH7 tumors, and apoptosis of HUH7 cells was recognized in the tumor. Next, HUH7 cells were injected into the portal vein in severe combined immunodeficiency mice to establish a hepatic tumor model. After inoculation with the tumor, HVJ-liposomes containing the AFPTK1 plasmid vector were injected into the portal vein via the splenic hilum, followed by GCV treatment. This gene therapy significantly inhibited the growth of tumors in the liver and markedly improved survival. Three injections of the AFPTK1 plasmid vector completely inhibited tumor growth. This procedure seems to have great potential for the treatment of multiple hepatic tumors.
language: eng
source:
identifier: ISSN: 0969-7128 ; PMID: 11402306 Version:1
fulltext: fulltext
issn:
  • 09697128
  • 0969-7128
url: Link


@attributes
ID1769571600
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid11402306
sourceidmedline
recordidTN_medline11402306
sourceformatXML
sourcesystemOther
pqid17859288
display
typearticle
titleHVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
creatorHirano, T ; Kaneko, S ; Kaneda, Y ; Saito, I ; Tamaoki, T ; Furuyama, J ; Tamaoki, T ; Kobayashi, K ; Ueki, T ; Fujimoto, J
ispartofGene therapy, January 2001, Vol.8(1), pp.80-3
identifierISSN: 0969-7128 ; PMID: 11402306 Version:1
subjectGenetic Therapy -- Methods ; Liver Neoplasms, Experimental -- Therapy ; Promoter Regions, Genetic -- Genetics ; Transfection -- Methods ; Alpha-Fetoproteins -- Genetics
descriptionSuicide gene therapy using ganciclovir (GCV) with transfection of the herpes thymidine kinase (HSVtk) gene has been studied for cancer therapy. The present study demonstrates an efficient method of suicide gene therapy for multiple hepatic tumors, involving repetitive transfection of the HSVtk gene driven by the alpha-fetoprotein (AFP) promoter using hemagglutinating virus of Japan (HVJ)-liposomes. AFP-producing cells (HUH7) and AFP-nonproducing cells (LS180) were injected subcutaneously (s.c.) to establish tumors in nude mice. Two plasmid constructs, bacterial LacZ gene driven by the AFP promoter (AFPLacZ), and HSVtk gene driven by the AFP promoter (AFPTK1) were encapsulated into the HVJ-liposome and used. When AFPLacZ was injected into the s.c. tumors, expression of LacZ gene was confined to HUH7 tumors. Repeated transfection of AFPTK1 followed by GCV treatment markedly suppressed growth of HUH7 tumors, and apoptosis of HUH7 cells was recognized in the tumor. Next, HUH7 cells were injected into the portal vein in severe combined immunodeficiency mice to establish a hepatic tumor model. After inoculation with the tumor, HVJ-liposomes containing the AFPTK1 plasmid vector were injected into the portal vein via the splenic hilum, followed by GCV treatment. This gene therapy significantly inhibited the growth of tumors in the liver and markedly improved survival. Three injections of the AFPTK1 plasmid vector completely inhibited tumor growth. This procedure seems to have great potential for the treatment of multiple hepatic tumors.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/11402306$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Hirano, T
1Kaneko, S
2Kaneda, Y
3Saito, I
4Tamaoki, T
5Furuyama, J
6Kobayashi, K
7Ueki, T
8Fujimoto, J
titleHVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
descriptionSuicide gene therapy using ganciclovir (GCV) with transfection of the herpes thymidine kinase (HSVtk) gene has been studied for cancer therapy. The present study demonstrates an efficient method of suicide gene therapy for multiple hepatic tumors, involving repetitive transfection of the HSVtk gene driven by the alpha-fetoprotein (AFP) promoter using hemagglutinating virus of Japan (HVJ)-liposomes. AFP-producing cells (HUH7) and AFP-nonproducing cells (LS180) were injected subcutaneously (s.c.) to establish tumors in nude mice. Two plasmid constructs, bacterial LacZ gene driven by the AFP promoter (AFPLacZ), and HSVtk gene driven by the AFP promoter (AFPTK1) were encapsulated into the HVJ-liposome and used. When AFPLacZ was injected into the s.c. tumors, expression of LacZ gene was confined to HUH7 tumors. Repeated transfection of AFPTK1 followed by GCV treatment markedly suppressed growth of HUH7 tumors, and apoptosis of HUH7 cells was recognized in the tumor. Next, HUH7 cells were injected into the portal vein in severe combined immunodeficiency mice to establish a hepatic tumor model. After inoculation with the tumor, HVJ-liposomes containing the AFPTK1 plasmid vector were injected into the portal vein via the splenic hilum, followed by GCV treatment. This gene therapy significantly inhibited the growth of tumors in the liver and markedly improved survival. Three injections of the AFPTK1 plasmid vector completely inhibited tumor growth. This procedure seems to have great potential for the treatment of multiple hepatic tumors.
subject
0Genetic Therapy -- Methods
1Liver Neoplasms, Experimental -- Therapy
2Promoter Regions, Genetic -- Genetics
3Transfection -- Methods
4Alpha-Fetoproteins -- Genetics
general
011402306
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
3MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline11402306
issn
009697128
10969-7128
rsrctypearticle
creationdate2001
addtitleGene therapy
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41200101
citationpf 80 vol 8 issue 1
startdate20010101
enddate20010131
lsr30VSR-Enriched:[eissn, pqid, doi, pages]
sort
titleHVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
authorHirano, T ; Kaneko, S ; Kaneda, Y ; Saito, I ; Tamaoki, T ; Furuyama, J ; Tamaoki, T ; Kobayashi, K ; Ueki, T ; Fujimoto, J
creationdate20010100
lso0120010100
facets
frbrgroupid7697483090317934626
frbrtype5
newrecords20190702
languageeng
creationdate2001
topic
0Genetic Therapy–Methods
1Liver Neoplasms, Experimental–Therapy
2Promoter Regions, Genetic–Genetics
3Transfection–Methods
4Alpha-Fetoproteins–Genetics
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Hirano, T
1Kaneko, S
2Kaneda, Y
3Saito, I
4Tamaoki, T
5Furuyama, J
6Kobayashi, K
7Ueki, T
8Fujimoto, J
jtitleGene Therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Hirano
1Kaneko
2Kaneda
3Saito
4Tamaoki
5Furuyama
6Kobayashi
7Ueki
8Fujimoto
aufirst
0T
1S
2Y
3I
4J
5K
au
0Hirano, T
1Kaneko, S
2Kaneda, Y
3Saito, I
4Tamaoki, T
5Furuyama, J
6Kobayashi, K
7Ueki, T
8Fujimoto, J
atitleHVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
jtitleGene therapy
risdate200101
volume8
issue1
spage80
pages80-83
issn0969-7128
formatjournal
genrearticle
ristypeJOUR
abstractSuicide gene therapy using ganciclovir (GCV) with transfection of the herpes thymidine kinase (HSVtk) gene has been studied for cancer therapy. The present study demonstrates an efficient method of suicide gene therapy for multiple hepatic tumors, involving repetitive transfection of the HSVtk gene driven by the alpha-fetoprotein (AFP) promoter using hemagglutinating virus of Japan (HVJ)-liposomes. AFP-producing cells (HUH7) and AFP-nonproducing cells (LS180) were injected subcutaneously (s.c.) to establish tumors in nude mice. Two plasmid constructs, bacterial LacZ gene driven by the AFP promoter (AFPLacZ), and HSVtk gene driven by the AFP promoter (AFPTK1) were encapsulated into the HVJ-liposome and used. When AFPLacZ was injected into the s.c. tumors, expression of LacZ gene was confined to HUH7 tumors. Repeated transfection of AFPTK1 followed by GCV treatment markedly suppressed growth of HUH7 tumors, and apoptosis of HUH7 cells was recognized in the tumor. Next, HUH7 cells were injected into the portal vein in severe combined immunodeficiency mice to establish a hepatic tumor model. After inoculation with the tumor, HVJ-liposomes containing the AFPTK1 plasmid vector were injected into the portal vein via the splenic hilum, followed by GCV treatment. This gene therapy significantly inhibited the growth of tumors in the liver and markedly improved survival. Three injections of the AFPTK1 plasmid vector completely inhibited tumor growth. This procedure seems to have great potential for the treatment of multiple hepatic tumors.
pmid11402306
doi10.1038/sj.gt.3301355
eissn14765462
oafree_for_read
date2001-01